First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.

Wednesday, June 19, 2024

Dr. Minal Barve

Click above link to view abstract.

ASCO 2024 Poster for Trial 23-22

ASCO 2024 Poster for Trial 23-22